Screener
Adaptive Biotechnologies ADPT Contract Liabilities, Non-Current
Contract Liabilities, Non-Current at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total current liabilities | 87,011 | 89,915 |
| Long-term liabilities | ||
| Operating lease liabilities, less current portion | 69,115 | 70,228 |
| Deferred revenue, less current portion | 807 | 1,006 |
| Revenue interest liability, net, less current portion | 124,749 | 126,566 |
| Other long-term liabilities | 20 | 20 |
| Total liabilities | 281,702 | 287,735 |
| Commitments and contingencies (Note 9) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's contract liabilities, non-current?
- Adaptive Biotechnologies (ADPT) reported contract liabilities, non-current of $807K in Q1 2026.
- How has Adaptive Biotechnologies's contract liabilities, non-current changed year-over-year?
- Adaptive Biotechnologies's contract liabilities, non-current decreased by 96.7% year-over-year, from $24.81M to $807K.
- What is the long-term trend for Adaptive Biotechnologies's contract liabilities, non-current?
- Over 5 years (2020 to 2025), Adaptive Biotechnologies's contract liabilities, non-current has grown at a -63.9% compound annual growth rate (CAGR), from $163.62M to $1.01M.
Ask your AI about Adaptive Biotechnologies's contract liabilities, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude